ClearView Wealth (ASX:CVW) and Zurich get the ACCC’s blessing to merge

APRA and the court are the last real hurdles to Clearview Wealth and Zurich joining forces!

ClearView Wealth (ASX:CVW) has knocked over one of the bigger hurdles standing between its shareholders and the proposed Zurich takeover. The ACCC has determined under the new mandatory merger regime that the Transaction may proceed, and it did so during phase 1 of the review rather than escalating into a deeper phase 2 probe.

For a deal that was first announced in February 2026, getting through the regulator at the first pass is the cleanest possible outcome. The 14-day review window opened yesterday, and assuming no third party files an application during that period, the ACCC Clearance condition under the scheme implementation deed is satisfied.

That leaves three boxes left to tick. APRA approval, a shareholder vote at the Scheme Meeting, and Court approval. The board still unanimously recommends shareholders vote in favour, and Crescent Capital Partners, which controls 53.0% of the register, has reconfirmed in writing that it intends to vote those shares in favour.

In other words, the path to completion is now narrower and the optionality for a counter-bidder is shrinking with every condition that falls.

Why a phase 1 ACCC clearance is the result the arbs wanted

Australia’s mandatory merger control regime only came into force on 1 January 2026, so the Zurich-ClearView deal is one of the early tests of how the ACCC will run the new framework. A phase 1 clearance signals the regulator did not see enough competition concern in the combined life insurance footprint to warrant the longer, more invasive phase 2 review.

That matters because phase 2 reviews are where deals get re-priced, re-shaped, or quietly walked away from. ClearView and Zurich avoided that entirely. For shareholders sitting on the deal spread, this is the outcome that materially compresses regulatory risk and pulls the implied completion probability up.

The only nuance worth flagging is the staleness clause. If the scheme is not implemented within 12 months of the determination, the ACCC’s approval lapses and the parties have to go back. Given the indicative timetable, that is not a realistic concern, but it is the kind of detail that exists for a reason.

Crescent at 53% effectively decides the shareholder vote

The shareholder vote at the Scheme Meeting requires the standard Requisite Majorities under the Corporations Act, meaning a 75% vote in value and a majority by number of those voting. Crescent Capital Partners holding or controlling 53.0% of the shares on issue is, in practical terms, decisive on the value test.

Crescent’s intention statement is qualified in the usual ways. It is conditional on the board continuing to recommend the deal, the Independent Expert continuing to conclude the Scheme is in shareholders’ best interests, and no superior proposal emerging. None of those qualifiers look stretched on current information.

We think the only realistic disruption from here is a competing bidder showing up with a clearly superior offer. After three months of public deal terms and an ACCC review now done, that window is closing rather than opening.

What’s left, and where the timing risk actually sits

APRA approval is the next regulatory step. Life insurance acquisitions involving offshore-controlled acquirers like Zurich are routine for APRA, and there is nothing in this transaction structure that suggests an unusual prudential concern. It is a process step rather than a thesis-defining event.

Court approval should come after the shareholder vote and is a largely procedural step provided the vote passes cleanly. The real timing variable is how quickly the Scheme Booklet, Independent Expert’s Report, and APRA engagement run in parallel over the coming weeks.

ClearView has flagged it will update shareholders on the timetable as required. The original indicative schedule from the February announcement remains in play.

The Bottom Line

With the ACCC done and Crescent locked in, the residual risk on this scheme has not been eliminated, but significantly narrowed given that the ACCC has blocked deals in the past. The remaining conditions are real but largely procedural, and the major shareholder mathematics make the vote outcome difficult to derail short of a superior proposal.

For investors still holding CVW, the trade is now essentially an arbitrage on the spread between the current price and the scheme consideration, adjusted for time value and the residual probability of a hiccup at APRA or Court. We think that residual risk has materially compressed today, even if the market reaction is muted.